| Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 18565394 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The purpose of this study was to compare estimates for revascularization and major adverse cardiac events (MACE) (death, myocardial infarction, repeat revascularization) in diabetic patients treated with paclitaxel- and sirolimus-eluting stents (PES and SES). BACKGROUND: Outcomes in diabetic patients treated with PES and SES have not been adequately evaluated. METHODS: We searched MEDLINE/EMBASE from January 2002 to February 2007 and identified abstracts/presentations from this period at major cardiology conferences. Randomized controlled trials (RCTs) and registries were included if data for diabetic patients treated with PES or SES were available. Point estimates with 95% confidence intervals (CIs) were computed as summary statistics. RESULTS: In RCTs (13 trials; n = 2,422) similar point estimates for target lesion revascularization (TLR) (PES: 8.6%, 95% CI 6.5% to 11.3%; SES: 7.6%, 95% CI 5.8% to 9.9%) and MACE (PES: 15.4%, 95% CI 12.4% to 19.1%; SES: 12.9%, 95% CI 8.5% to 19.2%) were observed. In head-to-head trials (4 RCTs), no difference in the likelihood of TLR (PES vs. SES) was observed (odds ratio [OR] 1.37, 95% CI 0.64 to 2.9, p = 0.42). In registries (16 registries; n = 10,156), point estimates for target vessel revascularization (TVR) (PES: 5.8%, 95% CI 3.9% to 8.5%; SES: 7.2%, 95% CI 4.6% to 11.2%) and MACE (PES: 10.1%, 95% CI 7.3% to 13.8%; SES: 11.9%, 95% CI 8.6% to 16.4%) were also similar. In registries reporting outcomes with both stents (8 registries for TVR and 7 registries for MACE), the likelihood of TVR (PES vs. SES) (OR 0.77, 95% CI 0.54 to 1.10, p = 0.15) and MACE (OR 0.83, 95% CI 0.68 to 1.01, p = 0.056) were nonsignificantly lower with PES. CONCLUSIONS: This analysis of over 11,000 diabetic patients treated with drug-eluting stents demonstrates single-digit revascularization rates. Furthermore, revascularization and MACE estimates are similar with both PES and SES. |
| | |
Authors:
|
Ehtisham Mahmud; Guilherme Bromberg-Marin; Vachaspathi Palakodeti; Lawrence Ang; Dana Creanga; Anthony N Demaria |
Related Documents
:
|
20945504 - Benfluorex and valvular heart disease: a cohort study of a million people with diabetes... 18071004 - Breast-feeding and type 2 diabetes in the youth of three ethnic groups: the search for ... 20967764 - Incidence of urinary tract infection in patients with type 2 diabetes. experience from ... 9146434 - The role of diabetes mellitus in the higher prevalence of tuberculosis among hispanics. 6360174 - Essentiality of insulin and prolactin for accumulation of rat casein mrnas. 22459614 - A cross-over study of the acute effects of espresso coffee on glucose tolerance and ins... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 51 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-06-20 Completed Date: 2008-07-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 2385-95 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiovascular Medicine, University of California-San Diego Medical Center, San Diego, California 92103-8784, USA. emahmud@ucsd.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Coronary Artery Disease / drug therapy, therapy* Coronary Restenosis / prevention & control Coronary Thrombosis / prevention & control Diabetes Mellitus / physiopathology* Drug-Eluting Stents* Female Humans Immunosuppressive Agents / therapeutic use* Male Middle Aged Odds Ratio Paclitaxel / therapeutic use* Randomized Controlled Trials as Topic Registries Risk Assessment Risk Factors Sirolimus / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Managing dyslipidemia in chronic kidney disease.
Next Document: ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of hig...